# Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas

> **NCT01434602** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 86 (actual)

## Conditions studied

- Brain Tumor
- Glioblastoma
- Anaplastic Glioma

## Interventions

- **DRUG:** everolimus
- **DRUG:** sorafenib

## Key facts

- **NCT ID:** NCT01434602
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-02
- **Primary completion:** 2020-10-19
- **Final completion:** 2021-07-13
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2022-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01434602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01434602, "Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01434602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*